LongeVC Portfolio Company Red Queen Bio Raises $15M to Strengthen AI-Driven Biosecurity
As AI systems accelerate both biological discovery and potential misuse, the core challenge is no longer identifying risks, but keeping pace with how quickly those risks can evolve. That requires defensive platforms that merge computational models with experimental validation and continuous threat mapping.
We are happy to share that Red Queen Bio, a LongeVC portfolio company spun out of HelixNano, has raised a $15 million seed round led by OpenAI to build exactly this type of infrastructure. The team has been working at the frontier of AI-guided biodefense for years, and the new funding reflects a wider acknowledgement that biosecurity must innovate at the same speed as AI.
The round builds on earlier collaboration between Red Queen Bio and OpenAI on AI biorisk-testing frameworks. With new capital, the company will expand into an integrated AI–wet lab pipeline aimed at detecting vulnerabilities earlier, validating them experimentally, and strengthening the broader biodefense ecosystem.